Annovis Bio Inc

NYSE:ANVSUnited States

Apr 2, 2024

Show headlines and story abstract

• DJ Annovis Bio Is Maintained at Buy by HC Wainwright & Co., from 9:07AM ET on Tuesday Apr 02, 2024 by Dow Jones

  9:07AM ET on Tuesday Apr 02, 2024 by Dow Jones
  Companies Mentioned: ANVS
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/ANVS/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 02, 2024 09:07 ET (13:07 GMT)
  

• Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results, from 7:30AM ET on Tuesday Apr 02, 2024 by GlobeNewswire

  7:30AM ET on Tuesday Apr 02, 2024 by GlobeNewswire
  Companies Mentioned: ANVS

• Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results, from 7:30AM ET on Tuesday Apr 02, 2024 by Dow Jones

  7:30AM ET on Tuesday Apr 02, 2024 by Dow Jones
  Companies Mentioned: ANVS
  
  This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company advises caution in reliance on forward-looking statements. Forward-looking statements include, without limitation, the Company's plans related to clinical trials. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those implied by forward-looking statements, including regarding patient enrollment, the effectiveness of buntanetap and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety and tolerability of buntanetap. See also additional risk factors set forth in the Company's periodic filings with the SEC, including, but not limited to, those risks and uncertainties listed in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC. All forward-looking statements in this press release are based on information available to the Company as of the date of this filing. The Company expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
  

• Press Release: Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results, from 7:30AM ET on Tuesday Apr 02, 2024 by Dow Jones

  7:30AM ET on Tuesday Apr 02, 2024 by Dow Jones
  Companies Mentioned: ANVS
  
  This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company advises caution in reliance on forward-looking statements. Forward-looking statements include, without limitation, the Company's plans related to clinical trials. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those implied by forward-looking statements, including regarding patient enrollment, the effectiveness of buntanetap and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety and tolerability of buntanetap. See also additional risk factors set forth in the Company's periodic filings with the SEC, including, but not limited to, those risks and uncertainties listed in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC. All forward-looking statements in this press release are based on information available to the Company as of the date of this filing. The Company expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.